Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis

NCT05152173 is registered in ClinicalTrials.gov with Endo USA Inc., a Keenova Therapeutics Company as lead sponsor.

NCT NCT05152173
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05152173 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Phase
Phase 2
Overall status
Completed
Start date
November 29, 2021
Completion date
January 10, 2023
Enrollment
176 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

plantar fibromatosis